Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events.
Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. Fujisaki T, et al. Among authors: iwashima a. Front Oncol. 2021 Sep 24;11:704475. doi: 10.3389/fonc.2021.704475. eCollection 2021. Front Oncol. 2021. PMID: 34631533 Free PMC article.
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.
Watanabe S, Ota T, Hayashi M, Ishikawa H, Otsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Miyabayashi T, Miura S, Tanaka H, Abe T, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Kikuchi T. Watanabe S, et al. Among authors: iwashima a. Cancer Med. 2020 May;9(9):3070-3077. doi: 10.1002/cam4.2974. Epub 2020 Mar 9. Cancer Med. 2020. PMID: 32150668 Free PMC article.
Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
Saida Y, Watanabe S, Abe T, Shoji S, Nozaki K, Ichikawa K, Kondo R, Koyama K, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Tsukada H, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Saida Y, et al. Among authors: iwashima a. Thorac Cancer. 2019 Nov;10(11):2106-2116. doi: 10.1111/1759-7714.13189. Epub 2019 Sep 10. Thorac Cancer. 2019. PMID: 31507098 Free PMC article.
A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401).
Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, Makino M, Iwashima A, Matsumoto N, Sato K, Ichikawa K, Abe T, Yoshizawa H, Kikuchi T. Okajima M, et al. Among authors: iwashima a. Transl Lung Cancer Res. 2021 Jan;10(1):252-260. doi: 10.21037/tlcr-20-649. Transl Lung Cancer Res. 2021. PMID: 33569309 Free PMC article.
Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.
Sato Y, Watanabe S, Ota T, Kushiro K, Fujisaki T, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Hayashi M, Ishikawa H, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Ohshima Y, Koya T, Kikuchi T. Sato Y, et al. Among authors: iwashima a. Transl Lung Cancer Res. 2021 Jul;10(7):3132-3143. doi: 10.21037/tlcr-21-198. Transl Lung Cancer Res. 2021. PMID: 34430353 Free PMC article.
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302).
Shoji S, Miura S, Watanabe S, Ohtsubo A, Nozaki K, Saida Y, Ichikawa K, Kondo R, Tanaka T, Koyama K, Tanaka H, Okajima M, Abe T, Ota T, Ishida T, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Shoji S, et al. Among authors: iwashima a. Transl Lung Cancer Res. 2022 Jul;11(7):1359-1368. doi: 10.21037/tlcr-22-89. Transl Lung Cancer Res. 2022. PMID: 35958345 Free PMC article.
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H. Miura S, et al. Among authors: iwashima a. Support Care Cancer. 2013 Sep;21(9):2575-81. doi: 10.1007/s00520-013-1835-2. Epub 2013 May 5. Support Care Cancer. 2013. PMID: 23644992 Clinical Trial.
A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H. Miura S, et al. Among authors: iwashima a. Invest New Drugs. 2017 Apr;35(2):227-234. doi: 10.1007/s10637-017-0436-1. Epub 2017 Feb 1. Invest New Drugs. 2017. PMID: 28150074 Clinical Trial.
197 results